gvtcx

QU496 - Provision of Cost Benefit Analysis of Carrier Screening for Genetic Disorders - AWARD

Birmingham City Council Published 18 Oct 2021 Contracts Finder

key details

Statuscomplete
Category (CPV) 71620000 +4 more
RegionWest Midlands
Deadline3 Sept 2021
Contract start18 Oct 2021
Contract end18 Apr 2022
Procedureopen
SME suitableYes
OCIDocds-b5fd17-34ed1952-7de2-4131-a3c7-3091eb410a8c

Award

SupplierValueDateStatus
UEA Consulting Ltd £59,950 17 Oct 2021 active

description

Birmingham City Council requires a supplier for the provision of a Desk Based Report on the Cost Benefit Analysis (CBA) of Genetic Autosomal Recessive Screening. This will be used to inform the action plan of the Birmingham Perinatal and Infant Mortality Strategy. We would like the report to include an estimate of service costs regarding stillbirths, perinatal mortality, infant mortality and lifetime associated with those that survive infancy. Costs can be based on historic service models in addition the estimates for the thresholds of cost effectiveness for each of the above. The costs should be specified for the NHS, social services and the wider costs to society.

For the purposes of developing our Peri-natal and Infant Mortality Strategy, Birmingham City Council (BCC) Public Health requires an evaluation that compares the cost of screening for autosomal recessive conditions with the economic benefits accruing from changes in the prevalence rates of stillbirths, peri-natal and infant mortality and health outcomes. The cost benefits should include the financial savings to services in the health, social care and education sectors and the wider society.

The CBA needs to be based on provision of screening women who are planning a pregnancy and the women and partners who are considered to be at risk from a genetic disorder with X-linked genetic conditions with a panel screening for multiple conditions.

The CBA needs to consider a Genetic Counselling component and the cost considerations for this element.

Your proposal must:

  • oDescribe your methodology for writing this report to include planning, mapping, modelling and reporting
  • oProvide a breakdown of total costs including key expenditure anticipated to deliver the project

The contract to undertake the CBA of autosomal recessive screening will be for a period of 6 months commencing 13th September 2021.

The Council will be using its free to use e-tendering system (in-tend) for the administration of this procurement process and potential suppliers must register with the system to be able to express an interest. If you wish to express an interest in this opportunity please click on the following link to access https://in-tendhost.co.uk/birminghamcc/ and submit your details to register. You will then be sent details on how to log on which will enable you to download all relevant tender documentation.

If you are unable to register with In-tend or have any questions or problems on how to use this web site please either email us at: cps@birmingham.gov.uk or call CPS Helpdesk on 0121 464 8000.

Your completed tender submission should be returned by noon on 3rd September 2021 via the 'in-tend' system https://in-tendhost.co.uk/birminghamcc

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
18 Oct 2021 Award (award) · e46a0024-f272-405c-bcda-ae1faec25320-477558

more from Birmingham City Council

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.